Insmed Announces That Data At American Diabetes Association Annual Meeting Will Highlight Drug Pipeline
RICHMOND, Va.--(BW HealthWire)--June 13, 2002--Insmed Incorporated (Nasdaq: INSM - News) today announced that results of Phase II clinical trials of INS-1 and SomatoKine® in patients with type 2 diabetes will be presented at three poster sessions at the American Diabetes Association's 62nd Annual Scientific Sessions.
The Company will present data from the most recent Phase II clinical trial of SomatoKine® for the treatment of type 2 diabetes and the Company will present two additional posters that will detail the results of additional analyses from previously reported clinical trial data with INS-1 in type 2 diabetes.
"In clinical trials to date, INS-1 has demonstrated improved glycemic control and a superior safety profile to existing oral insulin sensitizers. SomatoKine, a unique complex of recombinant proteins, has been shown to improve insulin sensitivity with fewer side effects than other therapies currently available to treat insulin resistance," explained Geoffrey Allan, Ph.D., president and chief executive officer of Insmed. "We're quite pleased with the opportunity to present this favorable data about two of our compounds."
The three abstracts to be presented follow, and may be viewed in full at the ADA's website www.diabetes.org/am02.
Poster # 605-P: D-Chiro-Inositol (INS-1) in Combination with Statins Synergistically Improves Lipid Profiles in Patients with Type 2 Diabetes.
Poster # 466-P: D-Chiro-Inositol (INS-1) Improves Beta Cell Function in Type 2 Diabetes Patients Receiving Sulfonylurea Therapy.
Poster # 577-P: A Double-blind, Randomized, Placebo-controlled Study to Determine the Dose Response Profile of SomatoKine® in Subjects with Type 2 Diabetes Mellitus Requiring Insulin Therapy.
The ADA Scientific Sessions are taking place at the Moscone Convention Center, in San Francisco, from Friday, June 14 until Tuesday, June 18. The posters will be on display 10:00AM-6:15PM on Saturday, June 15. The presenters will be available for questions and discussion 12:15-2:15PM and again 4:45-6:15PM during the poster session reception.
About INS-1
Insmed's orally active insulin sensitizer addresses large, unmet medical needs. An estimated 135 million people worldwide suffer from diabetes, with annual diabetes, health-related expenditures reaching $100 billion in the United States alone. Worldwide sales of the top three oral insulin sensitizers, GLUCOPHAGE, ACTOS and AVANDIA marketed by Bristol-Myers Squibb (NYSE:BMY - News), Eli Lilly (NYSE:LLY - News) and GlaxoSmithKline (NYSE:GSK - News) respectively, exceeded $4 billion in 2001. Despite this strong demand for these existing agents, most have less than optimal side effect profiles, creating a significant market opportunity for INS-1. The drug candidate has been in 18 clinical trials, over 1000 subjects and cumulative drug exposure of approximately 400 years with no drug related serious adverse events reported to date. In patients with type 2 diabetes, INS-1 significantly improves glycemic and lipid profiles. The company is also pioneering INS-1 as a treatment for polycystic ovary syndrome (PCOS), a significant women's health disorder that currently has no approved therapies.
About SomatoKine®
The company's product candidate, SomatoKine®, is being developed as an injectable insulin sensitizer and growth promoting agent. The drug is the recombinant form of human insulin-like growth factor-I (IGF-I) and its primary binding protein, IGFBP-3. SomatoKine is currently in clinical development for type 1 and type 2 diabetes, severe burn injury, and growth hormone insensitivity syndrome (GHIS). Insmed has received orphan drug designation for severe burn injury.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases. Further information is available at www.insmed.com.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
--------------------------------------------------------------------------------
Contact:
Insmed Incorporated, Richmond
Baxter Phillips, III, 804/565-3041, bphillips@insmed.com |
